Drug insight: Recent advances in male hormonal contraception.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic concepts and trial findings without systematic review methodology.
PubMed 16932251 · doi:10.1038/ncpendmet0069
What was done
This review examines advances in hormonal male contraception, detailing the mechanism of pituitary gonadotropin (luteinizing hormone and follicle-stimulating hormone) suppression via exogenous testosterone alone or combined with secondary agents such as progestogens or gonadotropin-releasing hormone antagonists across various delivery formulations.
What was found
Testosterone monotherapy caused azoospermia in 60-70% of men within 3 to 4 months. Male hormonal contraception overall demonstrated 95% efficacy in preventing pregnancy, with sperm count recovery usually occurring within 4 months after stopping treatment. Regimens combining long-acting injectable or implantable testosterone with oral, injectable, or implantable progestogens achieved complete suppression of spermatogenesis in 80-90% of men, with near-complete suppression in the remainder and no reported severe side effects.
Why it matters
Adding progestogens to testosterone substantially improves the rate of complete spermatogenic suppression compared to testosterone alone, offering a viable, reversible pharmacological approach to male contraception.
Limits
The abstract describes a non-systematic narrative review and does not state the number of studies or total participants evaluated. Quantitative safety margins, specific adverse event rates, and long-term metabolic outcomes are not reported.
Cited by
- supports Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis by inhibiting GnRH release from the hypothalamus and gonadotropins (LH and FSH) from the pituitary.